
Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma
October 22, 2018Onclive TeamLong-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treate
Updated on: October 24,2023
270

Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma
October 22, 2018Onclive TeamLong-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treate
Updated on:October 24,2023
270
